germacrone and Liver-Neoplasms

Germacrone is one of the main bioactive components in the traditional Chinese medicine Rhizoma curcuma. In this study, the anti-proliferative effect of germacrone on the human hepatoma cell lines and the molecular mechanism underlying the cytotoxicity of germacrone were investigated. Treatment of human hepatoma cell lines HepG2 and Bel7402 with germacrone resulted in cell cycle arrest and apoptosis in a dose-dependent manner as measured by MTT assay, flow cytometric and fluorescent microscopy analysis, while much lower effect on normal human liver cell L02 was observed. Flow cytometric analysis revealed that germacrone induced G2/M arrest in the cell cycle progression that was associated with an obvious decrease in the protein expression of cyclin B1 and its activating partner CDK1 with concomitant inductions of p21. Hoechst 33258 and Annexin V/PI staining results showed that the total cell number in apoptosis associated with a dose-dependent up-regulation of Bax and down-regulation of Bcl-2/Bcl-xl was increased. In the meantime, the up-regulation of p53 and reactive oxygen species increase were observed, which suggested that germacrone might be a new potent chemopreventive drug candidate for liver cancer via regulating the expression of proteins related to G2/M cell cycle and apoptosis, and p53 and oxidative damage may play important roles in the inhibition of human hepatoma cells growth by germacrone.

Topics: Anticarcinogenic Agents; Apoptosis; Carcinoma, Hepatocellular; CDC2 Protein Kinase; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Intracellular Space; Liver; Liver Neoplasms; M Phase Cell Cycle Checkpoints; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sesquiterpenes, Germacrane; Tumor Suppressor Protein p53